TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
The ministry: pharmaceutical main business revenue growth rate will exceed 10%
 
Author:中国铭铉 企划部  Release Time:2016-11-11 11:56:30  Number Browse:1254
 

Medical network - on November 8, the ministry issued today put forward of the pharmaceutical industry development planning guide, by 2020, China's pharmaceutical industry main business revenue growth rate above 10%, the industry scale enterprises r&d intensity reached more than 2% above, through the international advanced level of GMP certification enterprises reached more than 100, the added value of enterprises above designated size industrial energy consumption fell 18%, pharmaceutical industry overall quality improved.

"Five-year" period, the pharmaceutical industry output grew by an average of 13.4% a year over the scale, the main business revenue and profit growth rate of 17.4% and 14.5% respectively, are always located in the industrial industry forefront. "Accurate medical, translational medicine provides a new direction for new drug development and disease diagnosis and treatment, based on the breakthrough technology innovation medicine appear constantly, tumor immunotherapy, new technology such as cell therapy to speed up the pace." , said an official with the ministry of industry and information department of related medical instrument towards the direction of intelligent, networked, portable and development of new materials are widely used, the Internet, healthy big data bind to pharmaceutical products, medical services and injected new momentum for development industrial upgrading.

The pharmaceutical industry development planning guide from enhancing industrial innovation ability and so on eight aspects put forward the specific task deployment. The director said, to accelerate the pharmaceutical industry and a new generation of information technology depth fusion, development of new formats; Strict quality and safety supervision, and promote the chemical generics in key areas such as quality improvement; For urgent clinical needs by developing products, strengthening the construction of basic drugs supply ability; To guide corporate restructuring integration, build collaboration, green low carbon, intelligent efficient advanced manufacturing system, improve the level of production concentration and intensification.

 
Previous article:Anti-corruption major reform. Hospital officials into the state's supervision
Next article:The lowest price reference, secondary bargaining... Guizhou high-value consumables will be in
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粤公网安备 44011202000029号